These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28749905)

  • 1. The BALAD-2 and GALAD biomarker models for hepatocellular carcinoma.
    Johnson PJ
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):452-454. PubMed ID: 28749905
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
    Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [No Abstract]   [Full Text] [Related]  

  • 4. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
    Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear medicine and hepatocellular carcinoma.
    Galli G; Salvatori M; Valenza V
    Rays; 1990; 15(3):365-79. PubMed ID: 1963231
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical and immunologic diagnosis of cancer. Hepatocellular cancer.
    Hirai H
    Tumour Biol; 1987; 8(2-3):86-93. PubMed ID: 2452470
    [No Abstract]   [Full Text] [Related]  

  • 7. Adrenocortical carcinoma misdiagnosed as hepatocellular carcinoma.
    Chen HW; Chen YC; Hsieh MY; Juan YS
    Lancet Oncol; 2018 Aug; 19(8):e429. PubMed ID: 30102237
    [No Abstract]   [Full Text] [Related]  

  • 8. [The evidence and topics for the diagnosis of hepatocellular carcinoma].
    Nishimura T; Iijima H
    Nihon Shokakibyo Gakkai Zasshi; 2017; 114(9):1593-1601. PubMed ID: 28883288
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma.
    He J; Liu Y
    EBioMedicine; 2016 Oct; 12():4-5. PubMed ID: 27665049
    [No Abstract]   [Full Text] [Related]  

  • 10. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.
    Singal AG; Hoshida Y; Pinato DJ; Marrero J; Nault JC; Paradis V; Tayob N; Sherman M; Lim YS; Feng Z; Lok AS; Rinaudo JA; Srivastava S; Llovet JM; Villanueva A
    Gastroenterology; 2021 Jun; 160(7):2572-2584. PubMed ID: 33705745
    [No Abstract]   [Full Text] [Related]  

  • 11. State-of-the-art Hepatocellular Carcinoma Biomarker Detection by Biosensor Technology-a Review.
    Uygun ZO
    J Gastrointest Cancer; 2021 Sep; 52(3):1081-1085. PubMed ID: 34347247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges of Clinical Research on Hepatocellular Carcinoma.
    Kudo M; Kitano M; Sakurai T; Nishida N
    Dig Dis; 2015 Oct; 33(6):780-90. PubMed ID: 26488399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.
    Kimhofer T; Fye H; Taylor-Robinson S; Thursz M; Holmes E
    Br J Cancer; 2015 Mar; 112(7):1141-56. PubMed ID: 25826224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma?
    De Palma M; Coukos G; Semela D
    Hepatology; 2013 Apr; 57(4):1294-6. PubMed ID: 22911438
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging evidence of molecular biomarkers in hepatocellular carcinoma.
    Umeda S; Kanda M; Kodera Y
    Histol Histopathol; 2018 Apr; 33(4):343-355. PubMed ID: 28959824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γ-Glutamyl transferase and its role as a biomarker of systemic malignancies other than hepatocellular carcinomas.
    Kapoor S
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):387. PubMed ID: 23348021
    [No Abstract]   [Full Text] [Related]  

  • 17. Biomarkers for early diagnosis of hepatocellular carcinoma.
    Forner A; Bruix J
    Lancet Oncol; 2012 Aug; 13(8):750-1. PubMed ID: 22738800
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers for hepatocellular carcinoma.
    Roberts LR
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):223-34. PubMed ID: 27166603
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour markers of hepatocellular carcinoma.
    Kew MC
    J Gastroenterol Hepatol; 1989; 4(4):373-84. PubMed ID: 2562350
    [No Abstract]   [Full Text] [Related]  

  • 20. Dickkopf-1 and hepatocellular carcinoma.
    Tsai JF; Jeng JE; Chuang WL
    Lancet Oncol; 2012 Oct; 13(10):e410; author reply e410-1. PubMed ID: 23026825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.